Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Clinical Professor Murray Barclay

Murray Barclay

Clinical Pharmacologist / Gastroenterologist

MD, FRACP

Email murray.barclay@cdhb.health.nz

Clinical Professor Murray Barclay is a Clinical Pharmacologist half-time, a Gastroenterologist half-time, and Clinical Professor with the University of Otago.

His research interests include:

  • inflammatory bowel disease genetics and pharmacogenetics
  • optimising medicines in gastroenterology and rheumatology
  • immune modulating drugs including thiopurines, methotrexate and TNF antagonists
  • therapeutic drug monitoring.

He runs clinical trials of new medicines in gastroenterology and has an interest in web-based interactive teaching in medicine.

^ Top of page

Publications

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). Allopurinol dose escalation to achieve serum urate below 6 mg/dL: An open-label extension study. Annals of the Rheumatic Diseases. Advance online publication. doi: 10.1136/annrheumdis-2017-211873

Chambers, C., Frampton, C., & Barclay, M. (2017). Presenteeism in the New Zealand senior medical workforce: A mixed-methods analysis. New Zealand Medical Journal, 130(1449), 10-21. Retrieved from https://www.nzma.org.nz/journal

Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2017). A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology, 73, 71-78. doi: 10.1007/s00228-016-2133-y

Siripuram, V. K., Wright, D. F. B., Barclay, M. L., & Duffull, S. B. (2017). Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models. Journal of Pharmacokinetics & Pharmacodynamics. Advance online publication. doi: 10.1007/s10928-017-9530-4

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases. Advance online publication. doi: 10.1136/annrheumdis-2016-210872

Edited Book - Other

Begg, E., Barclay, M., Vella-Brincat, J., Gardiner, S. J., Doogue, M., McDermott, L., … Chambers, S., & Murdoch, D. (Eds.). (2004). Preferred Medicines List (8th ed.). Christchurch: The Caxton Press, 172p.

^ Top of page

Chapter in Book - Other

Frizelle, F., & Barclay, M. (2008). Constipation in adults. In C. Young (Ed.), Clinical evidence handbook: The international source of the best available evidence for effective health care. (pp. 167). UK: BMJ: Evidence Centre.

^ Top of page

Journal - Research Article

Stamp, L. K., Chapman, P. T., Barclay, M., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). Allopurinol dose escalation to achieve serum urate below 6 mg/dL: An open-label extension study. Annals of the Rheumatic Diseases. Advance online publication. doi: 10.1136/annrheumdis-2017-211873

Stamp, L. K., Chapman, P. T., Barclay, M. L., Horne, A., Frampton, C., Tan, P., … Dalbeth, N. (2017). A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases. Advance online publication. doi: 10.1136/annrheumdis-2016-210872

Siripuram, V. K., Wright, D. F. B., Barclay, M. L., & Duffull, S. B. (2017). Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models. Journal of Pharmacokinetics & Pharmacodynamics. Advance online publication. doi: 10.1007/s10928-017-9530-4

Wright, D. F. B., Doogue, M. P., Barclay, M. L., Chapman, P. T., Cross, N. B., Irvine, J. H., & Stamp, L. K. (2017). A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology, 73, 71-78. doi: 10.1007/s00228-016-2133-y

Chambers, C., Frampton, C., & Barclay, M. (2017). Presenteeism in the New Zealand senior medical workforce: A mixed-methods analysis. New Zealand Medical Journal, 130(1449), 10-21. Retrieved from https://www.nzma.org.nz/journal

Kannangara, D. R. W., Graham, G. G., Wright, D. F. B., Stocker, S. L., Portek, I., Pile, K. D., Barclay, M. L., … Stamp, L. K., & Day, R. O. (2017). Individualising the dose of allopurinol in patients with gout. British Journal of Clinical Pharmacology. Advance online publication. doi: 10.1111/bcp.13307

Chambers, C. N. L., Frampton, C. M. A., Barclay, M., & McKee, M. (2016). Burnout prevalence in New Zealand's public hospital senior medical workforce: A cross-sectional mixed methods study. BMJ Open, 6(11), e013947. doi: 10.1136/bmjopen-2016-013947

Huelsen, A., Fischer, J., Hegarty, J., Ashcroft, A., Frampton, C. M. A., & Barclay, M. L. (2016). The scratch test for identifying the lower liver edge is at least as accurate as percussion and is significantly more effective for young trainees: A randomised comparative trial. New Zealand Medical Journal, 129(1446), 53-63. Retrieved from http://www.nzma.org.nz/journal

Huelsen, A., Oumer, R., Ashcroft, A., Roberts, R. H., Coulter, G. N., Kelly, S. J., & Barclay, M. L. (2016). Achalasia: A 13-year, single-centre experience comparing endoscopic balloon dilation and laparoscopic Heller myotomy. New Zealand Medical Journal, 129(1433), 45-54. Retrieved from http://www.nzma.org.nz/journal

McCombie, A., Langlotz, T., Barclay, M., Walmsley, R., Regenbrecht, H., & Schultz, M. (2016). Systematic review of IBD smartphone apps for symptom monitoring and communication with healthcare professionals. Journal of mHealth, 3(3), 36-41. Retrieved from http://www.thejournalofmhealth.com/

Wright, D. F. B., Duffull, S. B., Merriman, T. R., Dalbeth, N., Barclay, M. L., & Stamp, L. K. (2016). Predicting allopurinol response in patients with gout. British Journal of Clinical Pharmacology, 81(2), 277-289. doi: 10.1111/bcp.12799

Hock, B. D., Stamp, L. K., Hayman, M. W., Keating, P. E., Helms, E. T. J., & Barclay, M. L. (2016). Development of an ELISA-based competitive binding assay for the analysis of drug concentration and anti-drug antibody levels in patients receiving adalimumab or infliximab. Therapeutic Drug Monitoring, 38(1), 32-41. doi: 10.1097/ftd.0000000000000229

Doecke, J. D., Simms, L. A., Zhao, Z. Z., Roberts, R. L., Fowler, E. V., Croft, A., … Barclay, M. L., Merriman, T. R., Gearry, R. B., … Radford-Smith, G. L. (2015). Smoking behaviour modifies IL23r-associated disease risk in patients with Crohn's disease. Journal of Gastroenterology & Hepatology, 30(2), 299-307. doi: 10.1111/jgh.12674

Chua, E. W., Cree, S., Barclay, M. L., Doudney, K., Lehnert, K., Aitchison, A., & Kennedy, M. A. (2015). Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers. Pharmacogenomics Journal, 15, 414-421. doi: 10.1038/tpj.2015.9

Roberts, R. L., & Barclay, M. L. (2015). Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics, 16(8), 891-903. doi: 10.2217/pgs.15.29

Chin, P. K. L., Wright, D. F. B., Zhang, M., Wallace, M. C., Roberts, R. L., Patterson, D. M., Jensen, B. P., Barclay, M. L., & Begg, E. J. (2014). Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs in R&D, 14(2), 113-123. doi: 10.1007/s40268-014-0045-9

Stamp, L. K., Merriman, T. R., Barclay, M. L., Singh, J. A., Roberts, R. L., Wright, D. F. B., & Dalbeth, N. (2014). Impaired response or insufficient dosage? Examining the potential causes of ”inadequate response” to allopurinol in the treatment of gout. Seminars in Arthritis & Rheumatism, 44(2), 170-174. doi: 10.1016/j.semarthrit.2014.05.007

Pan, S., Stamp, L. K., Duffull, S. B., Barclay, M. L., Dalrymple, J. M., Drake, J., Zhang, M., & Korell, J. (2014). Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clinical Pharmacokinetics, 53(12), 1161-1170. doi: 10.1007/s40262-014-0179-5

Korell, J., Duffull, S. B., Dalrymple, J. M., Drake, J., Zhang, M., Barclay, M. L., & Stamp, L. K. (2014). Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. British Journal of Clinical Pharmacology, 77(3), 493-497. doi: 10.1111/bcp.12209

Buffery, P. J., Allen, K. M., Chin, P. K. L., Moore, G. A., Barclay, M. L., & Begg, E. J. (2014). Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: Can the strategy be improved? Therapeutic Drug Monitoring, 36(1), 86-92. doi: 10.1097/FTD.0b013e31829dc940

Chin, P. K. L., Patterson, D. M., Zhang, M., Jensen, B. P., Wright, D. F. B., Barclay, M. L., & Begg, E. J. (2014). Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. British Journal of Clinical Pharmacology, 78(3), 630-638. doi: 10.1111/bcp.12366

Stamp, L. K., & Barclay, M. (2014). Therapeutic drug monitoring in rheumatic diseases: Utile or futile? Rheumatology, 53(6), 988-997. doi: 10.1093/rheumatology/ket355

Beaudoin, M., Goyette, P., Boucher, G., Lo, K. S., Rivas, M. A., Stevens, C., … and also Barclay, M., Gearry, R., & Roberts, R. (2013). Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genetics, 9(9), e1003723. doi: 10.1371/journal.pgen.1003723

Van Egmond, R., Barclay, M. L., Chin, P. K. L., Sies, C. W., & Florkowski, C. M. (2013). Biological variation of thiopurine methyltransferase enzyme activity: When has a significant change taken place? Annals of Clinical Biochemistry, 50(5), 473-478. doi: 10.1177/0004563212473441

Korell, J., Stamp, L. K., Barclay, M. L., Dalrymple, J. M., Drake, J., Zhang, M., & Duffull, S. B. (2013). A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells. Clinical Pharmacokinetics, 52(6), 475-485. doi: 10.1007/s40262-013-0052-y

Nasir, B. F., Griffiths, L. R., Nasir, A., Roberts, R., Barclay, M., Gearry, R. B., & Lea, R. A. (2013). An envirogenomic signature is associated with risk of IBD-related surgery in a population-based Crohn’s disease cohort. Journal of Gastrointestinal Surgery, 17(9), 1643-1650. doi: 10.1007/s11605-013-2250-1

Zhang, M., Moore, G. A., Barclay, M. L., & Begg, E. J. (2013). A simple high-performance liquid chromatography method for simultaneous determination of three triazole antifungals in human plasma. Antimicrobial Agents & Chemotherapy, 57(1), 484-489. doi: 10.1128/aac.00768-12

Nasir, B. F., Griffiths, L., Nasir, A., Roberts, R., Barclay, M., Gearry, R., & Lea, R. A. (2013). Perianal disease combined with NOD2 genotype predicts need for IBD-related surgery in Crohn's disease patients from a population-based cohort. Journal of Clinical Gastroenterology, 47(3), 242-245. doi: 10.1097/MCG.0b013e318258314d

Koning, M., Ailabouni, R., Gearry, R. B., Frampton, C. M. A., & Barclay, M. L. (2013). Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: A population-based, case-control study. Inflammatory Bowel Diseases, 19(4), 767-778. doi: 10.1097/MIB.0b013e31827f27c8

Falvey, J. D., Bentley, R. W., Merriman, T. R., Hampton, M. B., Barclay, M. L., Gearry, R. B., & Roberts, R. L. (2013). Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: An association study in New Zealand Caucasians and meta-analysis. World Journal of Gastroenterology, 19(39), 6656-6664. doi: 10.3748/wjg.v19.i39.6656

Chin, P. K. L., Vella-Brincat, J. W. A., Walker, S. L., Barclay, M. L., & Begg, E. J. (2013). Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Internal Medicine Journal, 43(7), 778-783. doi: 10.1111/imj.12170

Wright, D. F. B., Stamp, L. K., Merriman, T. R., Barclay, M. L., Duffull, S. B., & Holford, N. H. G. (2013). The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. European Journal of Clinical Pharmacology, 69(7), 1411-1421. doi: 10.1007/s00228-013-1478-8

International Multiple Sclerosis Genetic Consortium (IMSGC), and also Mason, D., Barclay, M., Roberts, R., & Gearry, R. (2013). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 45(11), 1353-1360. doi: 10.1038/ng.2770

Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P. B., Hui, K. Y., … Gearry, R., … and also Barclay, M., & Roberts, R. (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 119-124. doi: 10.1038/nature11582

Van Egmond, R., Chin, P., Zhang, M., Sies, C. W., & Barclay, M. L. (2012). High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Alimentary Pharmacology & Therapeutics, 35(10), 1181-1189. doi: 10.1111/j.1365-2036.2012.05084.x

Zhang, M., Moore, G. A., Fernyhough, L. J., Barclay, M. L., & Begg, E. J. (2012). Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry. Analytical & Bioanalytical Chemistry, 404(6-7), 2091-2096. doi: 10.1007/s00216-012-6284-0

Eglinton, T. W., Barclay, M. L., Gearry, R. B., & Frizelle, F. A. (2012). The spectrum of perianal Crohn's disease in a population-based cohort. Diseases of the Colon & Rectum, 55(7), 773-777. doi: 10.1097/DCR.0b013e31825228b0

Roberts, R. L., Gallo, L.-M. D., Barclay, M. L., Gómez-García, M., Cardeña, C., Merriman, T. R., Gearry, R. B., & Martin, J. (2012). Independent replication of an association of CNVR7113.6 with Crohn's disease in caucasians. Inflammatory Bowel Diseases, 18(2), 305-311. doi: 10.1002/ibd.21752

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2012). Furosemide increases plasma oxypurinol without lowering serum urate—a complex drug interaction: Implications for clinical practice. Rheumatology, 51(9), 1670-1676. doi: 10.1093/rheumatology/kes091

Roberts, R. L., & Barclay, M. L. (2012). Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease. Journal of Gastroenterology & Hepatology, 27(10), 1546-1554. doi: 10.1111/j.1440-1746.2012.07220.x

Eglinton, T. W., Roberts, R., Pearson, J., Barclay, M., Merriman, T. R., Frizelle, F. A., & Gearry, R. B. (2012). Clinical and genetic risk factors for perianal Crohn's disease in a population-based cohort. American Journal of Gastroenterology, 107, 589-596. doi: 10.1038/ajg.2011.437

Morgan, A. R., Han, D.-Y., Lam, W.-J., Triggs, C. M., Fraser, A. G., Barclay, M., Gearry, R. B., … Ferguson, L. R. (2011). Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. Human Immunology, 72, 1117-1127. doi: 10.1016/j.humimm.2011.08.011

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. Journal of Rheumatology, 38(12), 2540-2547. doi: 10.3899/jrheum.110481

Diaz-Gallo, L.-M., Espino-Paisán, L., Fransen, K., Gómez-García, M., van Sommeren, S., Cardeña, C., … Barclay, M. L., … Gearry, R. B., Roberts, R. L., … Merriman, T. R., … Martin, J. (2011). Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. Inflammatory Bowel Diseases, 17(11), 2287-2294. doi: 10.1002/ibd.21630

Rossin, E. J., Lage, K., Raychaudhuri, S., Xavier, R. J., Tatar, D., Benita, Y., International Inflammatory Bowel Disease Genetics Constortium, … and also Roberts, R., Barclay, M., & Gearry, R. (2011). Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genetics, 7(1), e1001273. doi: 10.1371/journal.pgen.1001273

Glubb, D. M., Gearry, R. B., Barclay, M. L., Roberts, R. L., Pearson, J., Keenan, J. I., McKenzie, J., & Bentley, R. W. (2011). NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease. World Journal of Gastroenterology, 17(23), 2829-2837. doi: 10.3748/wjg.v17.i23.2829

Gardiner, S. J., Gearry, R. B., Burt, M. J., Chalmers-Watson, T., Chapman, B. A., Ross, A. G., Stedman, C. A. M., … Barclay, M. L. (2011). Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology & Hepatology, 26(1), 49-54. doi: 10.1111/j.1440-1746.2010.06489.x

Stamp, L. K., Barclay, M. L., O'Donnell, J. L., Zhang, M., Drake, J., Frampton, C., & Chapman, P. T. (2011). Relationship between serum urate and plasma oxypurinol in the management of gout: Determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clinical Pharmacology & Therapeutics, 90(3), 392-398. doi: 10.1038/clpt.2011.113

More publications...